CD80 antibody
Quick Overview for CD80 antibody (ABIN951411)
Target
See all CD80 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Specificity
- This antibody recognises the murine CD80 cell surface protein, also known as B7-1.
-
Cross-Reactivity (Details)
- Species reactivity (tested):Mouse.
-
Purification
- Purified
-
Isotype
- IgG2a
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 0.2 mg/mL
-
Buffer
- PBS containing 0.09 % Sodium Azide as preservative and EIA grade BSA to bring total protein concentration to 4-5 mg/mL
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- CD80
-
Alternative Name
- CD80
-
Background
- CD80 is a member of the Ig superfamily, along with CD86 (B7-2), participates in T cell costimulation via interactions with CD28 and CTLA-4. CD80 is constitutively expressed on dendritic cells, monocytes, and peritoneal macrophages, and it is inducible on B cells by various means, including activation by LPS, IL-4, and the cross-linking of surface Ig. Expression of CD80 is greatly enhanced on splenic B cells following activation by LPS, with peak expression occurring between 48 and 72 hours. It has been reported that activation of purified B cells with LPS can induce CD80 expression in as few as 18 hours.Synonyms: Activation B7-1 antigen, B7-1, B7.1, BB1, CD28LG, CD28LG1, CTLA-4 counter-receptor B7.1, LAB7, T-lymphocyte activation antigen CD80
-
Gene ID
- 12519
-
NCBI Accession
- NP_033985
-
UniProt
- Q00609
-
Pathways
- TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
Target
-